This project aims to advance glioblastoma (GBM) diagnosis and therapy by developing a next-generation theranostic nanoplatform functionalized with artificial intelligence-designed dual-targeting peptides. By integrating targeted upconversion nanotechnology with multimodal imaging and synergistic therapy, the research seeks to overcome the blood-brain barrier (BBB) and enhance therapeutic precision, imaging contrast, and efficacy against aggressive adult brain tumors.

Key objectives include the optimized synthesis of iron-doped carbon-coated upconversion nanoparticles (Fe/C-UCNPs) with tunable optical properties, followed by AI-driven peptide functionalization and photosensitizer (Chlorin e6) loading to improve selective BBB crossing and tumor accumulation. Cutting-edge characterization methods—such as transmission electron microscopy (TEM), scanning electron microscopy (SEM), X-ray diffraction (XRD), dynamic light scattering (DLS) and Fourier-transform infrared spectroscopy (FTIR), will be employed to assess size, morphology, crystallinity, and multimodal imaging capability.

Building upon these findings, the study will refine the nanoprobes to optimize biocompatibility, reactive oxygen species generation, and dual photodynamic/photothermal therapy. Advanced microfluidic BBB-on-chip models that better mimic the human BBB and GBM microenvironment will be used to evaluate the real-time transport, targeting specificity, and therapeutic performance of the developed platform.

By combining innovations in AI-guided peptide engineering and design, advanced nanoprobes, and microfluidic tumor modeling, this project aspires to deliver safer, minimally invasive therapies for glioblastoma, paving the way for future precision oncology and translational nanomedicine strategies. The outcomes will provide new insights into multifunctional theranostic platforms and contribute to the broader advancement of brain tumor management.